SG11201808762XA - Diagnostic methods for patient specific therapeutic decision making in cancer care - Google Patents

Diagnostic methods for patient specific therapeutic decision making in cancer care

Info

Publication number
SG11201808762XA
SG11201808762XA SG11201808762XA SG11201808762XA SG11201808762XA SG 11201808762X A SG11201808762X A SG 11201808762XA SG 11201808762X A SG11201808762X A SG 11201808762XA SG 11201808762X A SG11201808762X A SG 11201808762XA SG 11201808762X A SG11201808762X A SG 11201808762XA
Authority
SG
Singapore
Prior art keywords
international
pecs
pct
street
aggregate
Prior art date
Application number
SG11201808762XA
Inventor
Judit Pongrácz
Judit Rapp
Evelin Rácz
Original Assignee
Humeltis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humeltis filed Critical Humeltis
Publication of SG11201808762XA publication Critical patent/SG11201808762XA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111011110111010101111101011111011101011101111100110111011111011110111111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ...... ... WO 2017/174609 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 5/09 (2010.01) kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/058034 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, 4 April 2017 (04.04.2017) KP, MD, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, TH, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 1605759.8 4 April 2016 (04.04.2016) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: HUMELTIS [HU/HU]; 20 Ififisag Utja, 7624 kind Pecs (HU). GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors: PONGRACZ, Judit, Erzsebet; Morolo street TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 11., 7694 Hossziiheteny (HU). RAPP, Judit; Banky Donat TJ, street 19., 7633 Pecs (HU). RACZ, Evelin; Csillagkoz DK, 11/b, 7626 Pecs (HU). LV, SM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (74) Agents: LEE, Nicholas, John et al.; Kilburn & Strode GW, KM, ML, MR, NE, SN, TD, TG). LLP, 20 Red Lion Street, London Greater London WC1R Published: 4PJ (GB). — with international search report (Art. 21(3)) = 1-1 C:r © 7r IN 11 IN 1-1 (54) Title: DIAGNOSTIC METHODS FOR PATIENT SPECIFIC THERAPEUTIC DECISION MAKING IN CANCER CARE 0 N (57) : The present invention relates to a 3-Dimensional (3D) tissue culture aggregate of cells derived from a neoplastic tis- sue sample, wherein < 30% of total number cells are cells capable of interfering with reaggregation. It also relates to a method of making such a 3D aggregate and a method for assessing the effectiveness of an anti-neoplasm treatment by measuring the effect of said treatment on the viability of a three dimensional (3D) neoplasm tissue culture aggregate.
SG11201808762XA 2016-04-04 2017-04-04 Diagnostic methods for patient specific therapeutic decision making in cancer care SG11201808762XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605759 2016-04-04
PCT/EP2017/058034 WO2017174609A1 (en) 2016-04-04 2017-04-04 Diagnostic methods for patient specific therapeutic decision making in cancer care

Publications (1)

Publication Number Publication Date
SG11201808762XA true SG11201808762XA (en) 2018-11-29

Family

ID=58609360

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808762XA SG11201808762XA (en) 2016-04-04 2017-04-04 Diagnostic methods for patient specific therapeutic decision making in cancer care

Country Status (13)

Country Link
US (1) US20190128870A1 (en)
EP (1) EP3440199A1 (en)
JP (1) JP2019513418A (en)
KR (1) KR20190003549A (en)
CN (1) CN109563486A (en)
AU (1) AU2017245629A1 (en)
CA (1) CA3019873A1 (en)
IL (1) IL262121A (en)
MX (1) MX2018012143A (en)
PH (1) PH12018502147A1 (en)
RU (1) RU2018138503A (en)
SG (1) SG11201808762XA (en)
WO (1) WO2017174609A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2015183920A2 (en) 2014-05-28 2015-12-03 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016061464A1 (en) 2014-10-17 2016-04-21 Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CN110062764A (en) 2016-12-05 2019-07-26 儿童医院医学中心 Colon organoid and its preparation and application
CN108130313B (en) * 2017-12-28 2021-04-30 杭州枫霖科技有限公司 Method for constructing three-dimensional glioma tissue based on biological 3D printing
KR102030127B1 (en) 2019-01-10 2019-10-08 주식회사 보타닉센스 Composition including undecane or undecanal as active ingredients for anti-allergy, improvement of atopic dermatitis, or skin regeneration
CN111690615B (en) * 2020-06-12 2022-10-25 江苏信安佳医疗科技有限公司 Special culture medium for nasopharyngeal carcinoma organoid and culture method without scaffold
KR102577816B1 (en) * 2022-06-08 2023-09-12 차의과학대학교 산학협력단 Preparation method of caf-integrated pancreatic cancer organoid and use thereof
CN117625541B (en) * 2024-01-26 2024-04-02 零壹人工智能科技研究院(南京)有限公司 Brain glioma organoid construction method and drug sensitivity detection method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0900819A2 (en) * 2009-05-05 2011-01-28 Pecsi Tudomanyegyetem Lung tissue culture
US20130012404A1 (en) 2010-01-19 2013-01-10 Osaka Prefectural Hospital Organization Culture method, evaluation method and storage method for cancer-tissue-derived cell mass or aggregated cancer cell mass
HUE029316T2 (en) * 2010-11-04 2017-03-28 Univ Of Pecs Lung tissue model
GB201100180D0 (en) * 2011-01-06 2011-02-23 Capsant Neurotechnologies Ltd Tumour cell and tissue culture
US20140128272A1 (en) 2012-11-08 2014-05-08 Osaka Prefectural Hospital Organization Method for Inducing Dormancy of Cancer Tissue-Derived Cell Mass and Method for Evaluating Treating Means with the Use of Cancer-Tissue-Derived Cell Mass
US10545133B2 (en) 2013-05-13 2020-01-28 The Johns Hopkins University Molecular signatures of invasive cancer subpopulations
US20160123960A1 (en) 2013-06-10 2016-05-05 Millennium Pharmaceuticals, Inc. Method for preparing three-dimensional, organotypic cell cultures and uses thereof
WO2015073724A1 (en) 2013-11-15 2015-05-21 Molecular Response, Llc 3d cell culture and ex vivo drug testing methods
TWI486451B (en) * 2013-12-11 2015-06-01 Ind Tech Res Inst Isolated human liver tumor cell line and method of agent screening
TWI461535B (en) * 2013-12-11 2014-11-21 Ind Tech Res Inst Isolated human liver tumor cell line and method of agent screening
US11180734B2 (en) 2014-06-20 2021-11-23 Rutgers, The State University Of New Jersey Single cell-derived organoids
WO2016022830A1 (en) 2014-08-06 2016-02-11 Oregon Health & Science University Three-dimensional bioprinted pancreatic tumor model
CN105062973B (en) * 2015-07-22 2018-04-17 中山大学 One plant carries HPV feminine gender penis squamous cell carcinomas system that TP53 is mutated and application thereof

Also Published As

Publication number Publication date
AU2017245629A1 (en) 2018-11-22
WO2017174609A1 (en) 2017-10-12
CA3019873A1 (en) 2017-10-12
CN109563486A (en) 2019-04-02
RU2018138503A (en) 2020-05-12
JP2019513418A (en) 2019-05-30
EP3440199A1 (en) 2019-02-13
RU2018138503A3 (en) 2020-08-18
KR20190003549A (en) 2019-01-09
MX2018012143A (en) 2019-10-09
US20190128870A1 (en) 2019-05-02
IL262121A (en) 2018-11-29
PH12018502147A1 (en) 2019-07-15

Similar Documents

Publication Publication Date Title
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201804934PA (en) Novel Compounds
SG11201809064QA (en) Chimeric neurotoxins
SG11201811719RA (en) Conjugates for targeted cell surface editing
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201810196RA (en) Cancer treatments
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro